Target-based antimicrobial drug discovery

Methods in Molecular Biology

Volumn 431, Issue , 2007, Pages 271-283

  Alksne, Lefa E ^a   Dunman, Paul M ^a  

^a NONE

Author keywords

Antibacterial; Antibacterial target; Antimicrobial chemotherapy; Drug discovery

Indexed keywords

ANTIINFECTIVE AGENT; BIOLOGICAL PRODUCT;

ANIMAL; ARTICLE; BACTERIAL GENOME; BACTERIAL INFECTION; BACTERIUM; DRUG EFFECT; DRUG SCREENING; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN; METHODOLOGY; MICROBIOLOGY; PHARMACEUTICS;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; BIOLOGICAL PRODUCTS; DRUG EVALUATION, PRECLINICAL; GENOME, BACTERIAL; HUMANS; TECHNOLOGY, PHARMACEUTICAL;

BACTERIA (MICROORGANISMS);

EID: 40549108631     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Article

References (48)

1. Lerner, C. G. and Beutel, B. A. (2002) Antibacterial drug discovery in the post-genomics era. Curr. Drug Targets Infect. Disord. 2, 109-119.
2. Miesel, L., Greene, J., and Black, T. A. (2003) Genetic Strategies for antibacterial drug discovery. Nat. Rev. Genet. 4, 442-456.
3. Monaghan, R. L. and Barrett, J. F. (2006) Antibacterial drug discovery-then, now and the genomics future. Biochem. Pharmacol. 71, 901-909.
4. Vila, J., Sanchez-Cespedes, J., and dirait, E. (2005) Old and new strategies for the discovery of antibacterial agents. Curr. Med. Chem. Antiinfect. Agents 4, 337-353.
5. Schmid, M. B. (2006) Do targets limit antibiotic discovery? Nat. Biotechnol. 24, 419-420.
6. Black, M. T. and Hodgson, J. (2005) Novel target sites in bacteria for overcoming antibiotic resistance. Adv. Drug Deliv. Rev. 57, 1528-1538.
7. Pucci, M. (2006) Use of genomics to select antibacterial targets. Biochem. Pharmacol. 71, 1066-1072.
8. Berg, C. M., Berg, D. E., and Groisman, E. A. (1989) Transposable elements and the genetic engineering of bacteria, in Mobile DNA (Berg, D. and Howe, M., eds.), American Society for Microbiology, Washington, DC, pp. 879-925.
9. Gerdes, S., Scholle, M., Campbell, J., et al. (2003) Experimental, determination and system, level, analysis of essential genes in Escherichia coli MG1655. J. Bacteriol. 185, 5673-5684.
10. Salama, N., Shepherd, B., and Falkow, S. (2004) Global transposon mutagenesis and essential gene analysis of Helicobacter pylori. J. Bacteriol. 186, 7926-7935.
11. Butler, M. S. and Buss, A. D. (2006) Natural products - the future scaffolds for novel antibiotics? Biochem. Pharmacol. 71, 919-929.
12. Becker, D., Selbach, M., Rollenhagen, C., Ballmaier, M., Meyer, T. F., Mann, M., and Bumann, D. (2006) Robust Salmonella metabolism limits possibilities for new antimicrobials. Nature 440, 303-307.
13. Silver, L. (2006) Does the cell wall of bacteria remain a viable source of targets for novel antibiotics? Biochem, Pharmacol. 71, 996-1005.
14. Projan, S. J. (2002) New (and not so new) antibacterial targets - from where and when will the novel drugs come? Curr. Opin. Pharmacol. 2, 513-522.
15. Georgopapadakou, N. H. (2004) Beta-lactamase inhibitors: evolving compounds for evolving resistance targets. Expert Opin. Investig. Drugs 13, 1307-1318.
16. Rogers, B. L. (2004) Bacterial targets to antimicrobial leads and development candidates. Curr. Opin. Drug Discov. Dev. 7, 211-222.
17. Halliday, J., McKeveney, D., Muldoon, C., Rajaratnam, P. and Meutermans, W. (2006) Targeting the forgotten transglycosylases. Biochem. Pharmacol. 71, 957-967.
18. Silver, L. L. (2003) Novel inhibitors of bacterial cell wall synthesis. Curr. Opin. Microbiol. 6, 431-438.
19. Sutcliffe, J. A. (2005). Improving on nature: antibiotics that target the ribosome. Curr. Opin. Microbiol. 8, 534-542.
20. Alksne, L. E., Anthony, R. A., Liebman, S. W., and Warner, J. R. (1993). An accuracy center in the ribosome conserved over 2 billion years. Proc. Natl. Acad. Sci. U.S.A. 90, 9538-9541.
21. Franceschi, F. and Duffy, E. M. (2006) Structure-based drug design meets the ribosome. Biochem. Pharmacol. 71, 1016-1025.
22. Ebright, R. H. (2000) RNA polymerase: structural similarities between bacterial RNA polymerase and eukaryotic RNA polymerase II. J. MoL Biol. 304, 687-98.
23. Brück, I. and O'Donnell, M. (2000) The DNA replication machine of a gram-positive organism. J. Biol. Chem. 275, 28971-28983.
24. Bermingham, A. and Derrick, J. P. (2002) The folic acid biosynthesis pathway in bacteria: evaluation of potential for antibacterial drug discovery. Bioessays 24, 637-648.
25. Heath, R. J., White, S. W., and Rock, C. O. (2002) Inhibitors of fatty acid synthesis as antimicrobial chemotherapeutics. Appl. Microbiol. Biotechnol. 58, 695-703.
26. Zhao, L., Allanson, N. M., Thomson, S. P., Maclean, J. K., Barker, J. J., Primrose, W. U., Tyler, P. D., and Lewendon, A. (2003) Inhibitors of phosphopantetheine adenylyltransferase. Eur. J. Med. Chem. 38, 345-349.
27. Hutton, C. A., Southwood, T. J., and Turner, J. J. (2003) Inhibitors of lysine biosynthesis as antibacterial, agents. Mini Rev. Med. Chem. 3, 115-127.
28. Gunderson, C. W. and Segall, A. M. (2006) DNA repair, a novel, antibacterial target: IIolliday junction-trapping peptides induce DNA damage and chromosome segregation defects. Mol. Microbiol. 59, 1129-1148.
29. Pohlmann, J. and Brotz-Oesterhelt, H. (2004) New aminoacyl-tRNA synthetase inhibitors as antibacterial agents. Curr. Drug Targets Infect. Disord. 4, 261-272.
30. Clements, J. M., Ayscough, A. P., Keavey, K., and East, S. P. (2002) Peptide deformylase inhibitors, potential, for a new class of broad spectrum, antibacterials. Curr. Med. Chem. Antiinfect. Agents 1, 239-249.
31. Johnson, K. W., Lofland, D., and Moser, H. E. (2005) PDF inhibitors: an emerging class of antibacterial, drugs. Curr. Drug Targets Infect. Disord. 5, 39-52.
32. Leeds, J. A., Schmitt, E. K., and Krastel, P. (2006) Recent developments in antibacterial drug discovery: microbe-derived natural products - from collection to the clinic. Expert Opin. Investig. Drugs 15, 211-226.
33. Alksne, L. E. and Projan, S. J. (2000) Bacterial virulence as a target, for antimicrobial chemotherapy, [erratum appears in Curr. Opin. Biotechnol. 2001 Feb;12(1):112]. Curr. Opin. Biotechnol. 11, 625-636.
34. Otto, M. (2004) Quorum-sensing control in Staphylococci - a target for antimicrobial drug therapy? FEMS Microbiol. Lett. 241, 135-141.
35. Nordfelth, R., Kauppi, A. M., Norberg, II. A., Wolf-Watz, H., and Elofsson, M. (2005) Small-molecule inhibitors specifically targeting type III secretion. Infect. Immun. 73, 3104-3114.
36. Posner, B. A. (2005) High-throughput screening-driven lead discovery: meeting the challenges of finding new therapeutics. Curr. Opin, Drug Discov. Dev. 8, 487-494.
37. Goddard, J. -P. and Reymond, J. -L. (2004) Enzyme assays for high-throughput screening. Curr. Opin. Biotechnol. 15, 314-322.
38. Allison, R. D. (1997) Kinetic assay methods in Current Protocols in Molecular Biology, Supplement 40, Appendix 311, John Wiley & Sons, Inc., pp. A.3H.1-A.3H.10.
39. Lipinski, C. A. (2000) Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods 44, 235-249.
40. Donadio, S., Carrano, L., Brandi, L., Serina, S., Soffientini, A., Raimondi, E., Montanini, N., Sosio, M., and Gualerzi, C. O. (2002) Targets and assays for discovering novel, antibacterial agents. J. Biotechnol. 99, 175-185.
41. Thomson, C. J., Power, E., Ruebsamen-Waigmann, H., and Labischinski, H. (2004) Antibacterial research and development in the 21(st) Century-an industry perspective of the challenges. Curr. Opin. Microbiol. 7, 445-450.
42. Lundqvist, T. (2005) The devil is still in the details-driving early drug discovery forward with biophysical experimental methods. Curr. Opin. Drug Discov. Devel. 8, 513-519.
43. Mills, S. D. (2006) When will the genomics investment pay off for antibacterial discovery? Biochem. Pharmacol. 71, 1096-1102.
44. Krumrine, J., Raubacher, F., Brooijmans, N., and Kuntz, I. (2003) Principles and methods of docking and ligand design, in Structural Bioinformatics (Weissig, H. and Bourne, P. E., eds.), Wiley, Indianapolis, IN, pp. 441-476.
45. Schmid, M. B. (2004) Seeing is believing: the impact of structural, genomics on antimicrobial drug discovery. Nat. Rev. Microbiol. 2, 739-746.
46. Poole, K. (2004) Uninhibited antibiotic target discovery via chemical genetics. Nat. Biotechnol. 22, 1528-1529.
47. Li, X., Zolli-Juran, M., Cechetto, J. D., Daigle, D. M., Wright, G. D., and Brown, E. D. (2004) Multicopy suppressors for novel antibacterial compounds reveal targets and drug efflux susceptibility. Chem. Biol. 11, 1423-1430.
48. Singh, S. B. and Barrett, J. F. (2006) Empirical antibacterial drug discovery-foundation in natural products. Biochem. Pharmacol. 71, 1006-1015.